Haleon (LON:HLN) Earns “Sector perform” Rating from Royal Bank Of Canada

Haleon (LON:HLN)‘s stock had its “sector perform” rating restated by analysts at Royal Bank Of Canada in a report released on Thursday, MarketBeat Ratings reports. They presently have a GBX 370 ($4.91) target price on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 1.14% from the company’s current price.

Haleon Stock Performance

Shares of LON:HLN opened at GBX 365.83 ($4.86) on Thursday. The business has a fifty day moving average of GBX 381.70 and a 200-day moving average of GBX 385.07. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. Haleon has a twelve month low of GBX 346.10 ($4.59) and a twelve month high of GBX 419.50 ($5.57). The firm has a market cap of £33.02 billion, a PE ratio of 30.77, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 31st. The company reported GBX 8.90 ($0.12) EPS for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. On average, equities research analysts predict that Haleon will post 19.5033282 EPS for the current fiscal year.

Insider Activity at Haleon

In related news, insider Blathnaid Bergin acquired 6,145 shares of the company’s stock in a transaction that occurred on Friday, May 16th. The stock was purchased at an average price of GBX 404 ($5.36) per share, for a total transaction of £24,825.80 ($32,951.69). Also, insider Marie-Anne Aymerich acquired 21,300 shares of Haleon stock in a transaction on Friday, May 9th. The shares were purchased at an average cost of GBX 405 ($5.38) per share, for a total transaction of £86,265 ($114,500.93). 10.74% of the stock is currently owned by company insiders.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.